Shares of Aurobindo Pharma Ltd were trading almost 2% lower on Tuesday, 26 August, despite its subsidiary gaining regulatory approval in the United Kingdom to market its cancer treatment medicine.

CuraTeQ Biologics s.r.o., Aurobindo Pharma’s wholly-owned step-down subsidiary, has received marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to market Dazublys, a trastuzumab biosimilar version, according to a filing.

The present development comes after Dazublys received clearance from the European Commission (EC) for the European Union market in July 2025.

Dazublys is a drug used to treat HER2-positive breast and gastric cancer. The medicine affects the HER2 protein, which promotes tumour growth.

CuraTeQ’s clearance is the fourth biosimilar to receive MHRA approval, following Bevqolva in December 2024, Zefylt in May 2025, and Dyrupeg in June 2025. Dazublys, Zefylti, and Dyrupeg have also received permission in the larger European Union market, according to the business.

Santhanam Subramanian, Chief Financial Officer (CFO) of Aurobindo Pharma, confirmed in an exclusive interview on 21 August that the company has entered into a Non-Disclosure and Confidentiality agreement for its potential acquisition of Zentiva, and that talks are currently at a “very early stage.”

According to Subramanian, Zentiva’s involvement in Aurobindo Pharma’s strategic goal makes sense given Zentiva’s European basis; nevertheless, any concrete pronouncements on the prospective outcome are premature due to the early stage of negotiations. If a deal is reached, Subramanian thinks that an announcement will be made within the next two months.

Aurobindo Pharma currently has $140 million in assets and generates 75% of its income from the US and European markets, bolstering its excellent financial position.

Subramanian emphasised that, while examining large firms for acquisitions is not fundamentally incorrect, the company will exercise diligence to prevent overpayment in any potential transaction. He also stated that Aurobindo Pharma would prefer to agree to deals involving single-digit multiples.

At 1:15 pm, the shares of Aurobindo Pharma were trading 1.79% lower at Rs 1,048.30 on NSE.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!